Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
incarvine C
- Development stage
- Unknown
- Lead developer
- Qinghai University
01
Overview
incarvine C: sourced facts only. name: "In summary, these findings not only reveal the mechanism of incarvine C but also provide a new molecular template for Rac1 inhibitors and identify a promising candidate for breast cancer treatment." [PMID:38833990]; target: "In summary, these findings not only reveal the mechanism of incarvine C but also provide a new molecular template for Rac1 inhibitors and identify a promising candidate for breast cancer treatment." [PMID:38833990]; developer: "State Key Laboratory of Plateau Ecology and Agriculture, Qinghai University, 251 Ningda Road, Xining 810016, Qinghai, China; Department of Pharmacy, Medical College of Qinghai University, 16 Kunlun Road, Xining 810016, Qinghai, China." [PMID:38833990]
02
Targets
RAC1 (Rac family small GTPase 1)
Beyond the preview
Go deeper on incarvine C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on incarvine C.